The Advisory Board Co. (NASDAQ:ABCO)‘s stock had its “outperform” rating restated by William Blair in a report issued on Tuesday.
A number of other brokerages also recently commented on ABCO. Credit Suisse Group AG reiterated a “buy” rating and set a $50.00 price objective on shares of The Advisory Board in a research report on Friday, September 16th. Zacks Investment Research upgraded The Advisory Board from a “hold” rating to a “strong-buy” rating and set a $48.00 price objective on the stock in a research report on Monday, August 1st. Oppenheimer Holdings Inc. set a $45.00 price objective on The Advisory Board and gave the stock a “buy” rating in a research report on Thursday, July 28th. Cantor Fitzgerald reiterated a “hold” rating on shares of The Advisory Board in a research report on Friday, August 19th. Finally, Raymond James Financial Inc. downgraded The Advisory Board from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 19th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The Advisory Board presently has a consensus rating of “Buy” and a consensus price target of $43.40.
The Advisory Board (NASDAQ:ABCO) opened at 43.41 on Tuesday. The company’s market cap is $1.75 billion. The stock’s 50 day moving average price is $42.44 and its 200-day moving average price is $36.10. The Advisory Board has a 52-week low of $18.87 and a 52-week high of $54.84.
The Advisory Board (NASDAQ:ABCO) last announced its quarterly earnings data on Wednesday, July 27th. The company reported $0.47 EPS for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.13. The Advisory Board had a positive return on equity of 11.59% and a negative net margin of 10.21%. The firm had revenue of $198.40 million for the quarter, compared to the consensus estimate of $196.49 million. During the same quarter last year, the business posted $0.40 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. On average, equities analysts predict that The Advisory Board will post $1.86 earnings per share for the current fiscal year.
In related news, insider Evan R. Farber sold 2,924 shares of the business’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $40.95, for a total transaction of $119,737.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert W. Musslewhite sold 5,500 shares of the business’s stock in a transaction on Monday, September 12th. The stock was sold at an average price of $43.09, for a total value of $236,995.00. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Freshford Capital Management LLC boosted its position in The Advisory Board by 172.0% in the second quarter. Freshford Capital Management LLC now owns 546,967 shares of the company’s stock valued at $19,357,000 after buying an additional 345,867 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in The Advisory Board during the second quarter valued at about $1,703,000. Vista Equity Partners Management LLC acquired a new position in The Advisory Board during the second quarter valued at about $6,412,000. Paloma Partners Management Co acquired a new position in The Advisory Board during the second quarter valued at about $259,000. Finally, A.R.T. Advisors LLC boosted its position in The Advisory Board by 32.9% in the second quarter. A.R.T. Advisors LLC now owns 56,871 shares of the company’s stock valued at $2,012,000 after buying an additional 14,090 shares in the last quarter.
The Advisory Board Company Profile
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.
Receive News & Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related companies with MarketBeat.com's FREE daily email newsletter.